https://www.selleckchem.com/pr....oducts/msu-42011.htm
The increasing use of large panel next-generation sequencing technologies in clinical settings has facilitated the identification of pan-cancer biomarkers, which can be diagnostic, prognostic, predictive, or most importantly, actionable. To discuss recently approved and emerging pan-cancer and multihistology biomarkers as well as testing methodologies. The US Food and Drug Administration approval documents, National Comprehensive Cancer Network guidelines, literature, and author's own publications. Since 2017, the US Food and Drug Adm
Aimer
Commentaire
Partagez
